




The Self-Charging Heart

Varsha Venkatapathy
Nalaya Giraud

**Every 5 minutes
a pacemaker patient
undergoes surgery...
just to change a battery**






Problem Snapshot



- 1 million new pacemaker implants every year worldwide
- Battery life only 5 – 10 years \Rightarrow frequent generator replacements
- 100 000 replacement surgeries annually—each adds infection & lead-failure risk
- Average replacement bill \approx \$20 000; global burden tops \$2 – 3 billion
- Extra operations mean anxiety, hospital stays, and lost quality of life.

Why current energy-harvesting solutions fall short


Approach	Key Limitations	Power Density
 RF Coupling	✗ Requires alignment ✗ Bulky	< 100 μW
 Thermoelectric	✗ Requires temp gradient	Few μW
 MEMS Spring	✗ Organ motion ✗ Off-axis inefficiency	Hundreds nW

Why current energy-harvesting solutions fall short


Existing Problem Solutions

- RF / inductive coupling: needs precise coil alignment, bulky chargers; < 100 μW output.
- Thermoelectric harvesters: rely on core-skin gradient \rightarrow only a few μW .
- Spring-suspended MEMS generators: hundreds nW, off-axis losses, degrade in Ti can.
- None satisfy > 10 μW , compact size, and alignment-free implantation.

The Self-Charging Heart – How the Technology Works



The Self-Charging Heart – Why It Matters



How Do We Bring I-TENG to Patients?

Challenges to Adoption

Limited power in low-activity patients

Biocompatibility & long-term safety

Regulatory complexity (e.g. 510(k))

Manufacturing & quality control

Patient variability

CONCLUSION

- I-TENG enables battery-free cardiac pacing
 - ◀ Converts natural body motion into usable electrical power
- Reduces surgical risk and improves patient quality of life
- Proven effective in animal studies
 - ◀ Recharged pacemaker and responded to heart rate changes
- Next Steps:
 - ◀ Miniaturization & material optimization
 - ◀ Long-term safety and biocompatibility testing in humans
 - ◀ Regulatory submission and first-in-human trials